Biocon Bets Big on Insulin, Eyes GLP-1 Drugs for Future Growth
Bengaluru – Biocon Biologics, the biopharmaceutical arm of Biocon Ltd, is strengthening its foothold in the global insulin market while making a decisive move into the booming GLP-1 drug segment.…
Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base
Bengaluru-based biopharmaceutical firm Biocon on Monday launched a qualified institutions placement (QIP) to raise Rs 4,500 crore. As part of the offering, the firm will issue up to 139 million…
Biocon Q4 net profit surges 153%, biosimilars, generics drive growth
Biocon, India’s leading biopharmaceutical company, reported a 153 percent year-on-year (YoY) jump in net profit for the fourth quarter of FY25, led by strong performances in its biosimilars and generics…
All about Insulin Aspart that promted CBI to arrest Jt. Drug Controller of India
New Delhi: Dr. Eswara Reddy, Joint Drug Controller of India had been arrested by CBI on Monday last with an employee of Bengaluru-based pharmaceutical company, Biocon Biologics and others…
